Search
Aardvark Therapeutics CEO Tien Lee on this month's $85M series C and leveraging TAS2R to modulate hunger and as a weight loss strategy
Tien Lee describes how TAS2R is a bitter taste receptor that naturally activates gut hormones and gut-brain signaling and can be used to dam
May 28, 2024
Uniquity Bio's CEO on exiting stealth mode with $300M in funding from its parent Blackstone to go after TSLP in the I&I space
Brian Lortie describes how Blackstone has launched the company and the multiple advantages this relationship brings, why TSLP, and the...
May 28, 2024
With key EHA data coming up, Shattuck Labs looks to build on its hypothesis that adding an immune agonism component will transform the SIRPα space
Co-Founder and CEO Taylor Schreiber describes the bi-specific fusion protein construct he is co-inventor of and why he believes it is...
May 24, 2024
CRO Keys to Success: Clinical Pharmacology Modeling and Simulation
Allucent's Katy Moore, PharmD, RPh, describes the importance of 'Clinical Pharmacology Modeling and Simulation' to designing clinical...
May 23, 2024
William Blair analyst Matt Phipps joins BiotechTV for Analyst Thursdays from Research Triangle Park, North Carolina
Matt Phipps gives his take on biotech and discusses #ATS2024 data, Amgen and Keros' obesity programs, recent acquisitions by GenMab and...
May 23, 2024
The CEO of the North Carolina Biotechnology Center talks about growing biotech in the state
Doug Edgeton describes the growth that has taken place since North Carolina Biotechnology Center was founded four decades ago, and what...
May 22, 2024
Humacyte's CEO demonstrates the bioengineered human arteries the company has developed and that is in front of FDA with an August decision date for its BLA
Laura Niklason shows us what Humacyte's Human Acellular Vessel (HAV) looks like, describes how it is manufactured, explains its utility,...
May 22, 2024
The Chordoma Foundation in Raleigh is not only a resource for patients, but also works to advance drug development for this rare type of cancer
Joining us from their lab space in Raleigh, Executive Director Josh Sommer and CSO Dan Freed introduce us to chordoma and describe the...
May 22, 2024
A top Research Triangle based venture capital investor shares an overview of the life sciences ecosystem in North Carolina
Hatteras Venture Partners' Clay Thorp describes the growth of North Carolina's biotech industry during his firm's 20+ years of...
May 21, 2024
BioCryst aims to leverage its commercial success to accelerate a robust pipeline based on structure-guided drug design
CEO Jon Stonehouse describes how making it across the finish line with Orladeyo has put BioCryst in a position after may decades of drug...
May 21, 2024
The CEO of Context Therapeutics on raising $100M for a Claudin 6 x CD3 bispecific this month
Martin Lehr describes how Nextech enabled this private placement that may allow the company to accelerate clinical development to...
May 21, 2024
ATS2024: Gossamer Bio presented open label extension data for seralutinib, an inhibitor of PDGFR, CSF1R, and c-KIT, in PAH showing durability of effect at 72 weeks
CEO Faheem Hasnian and trial investigator Olivier Sitbon describe how some patients seem to not just be maintaining benefit, but...
May 20, 2024
ATS2024: Endeavor BioMedicines' Hedgehog inhibitor showed improvements in lung function, capacity, and other measures at 12-weeks in IPF
John Hood describes how the 12 week data Endeavor is witnessing is giving the company optimism that it might be reversing, rather than...
May 20, 2024
Philadelphia's Wistar Institute was awarded an additional $650K grant this week to fund its Biomedical Technician Training Program that helps open the door to jobs in STEM
Dean of Biomedical Studies Kristy Shuda McGuire describes how the BTT program trains community college and other students in lab work,...
May 17, 2024
Biotheryx's CEO on the company's protein degradation platform and CDK4/6 program that is IND cleared and will be entering the clinic
Leah Fung describes how Biotheryx is leveraging the E3 ligase Cereblon to enable its protein degradation, and discusses the lead CD4/6...
May 16, 2024
Gauging biotech investor sentiment with RBC's Healthcare Desk Sector Strategist
Chris McCarthy describes how investors are anticipating upcoming binary events and how they have been talking about broader market issues.
May 14, 2024
Catching up with Roberto Bellini one year after he sold BELLUS Health to GSK for $2 billion
Roberto Bellini introduces us to his new investment firm and looks back on lessons learned from selling BELLUS to GSK.
May 14, 2024
A banker's perspective on the current state of biotech with RBC's Noël Brown
Noël Brown shares his thoughts on the IPO market and its pipeline, following-on offerings, and takaways from the RBC Capital Markets...
May 14, 2024
PTC Therapeutics's CEO summarizes a busy year ahead of regulatory decisions and data
Dr. Matthew Klein provides updates on Translarna, Sepiapterin, Vatiquinone, Utreloxastat, PTC518, and more.
May 14, 2024
Pliant's CEO on targeting integrins to treat fibrotic diseases like IPF and liver disease
Bernard Coulie gives a deep dive into Pliant's IPF program, including news released this morning relating to patient PET scans.
May 14, 2024
.png){kind=logo}
